Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant ... a 1:1 ratio to receive oral apixaban at a reduced (2.5 ...

A study shows reduced-dose apixaban effectively prevents recurrent blood clots in cancer patients, lowering bleeding risks ...

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Summary Apixaban is an oral ... regimen in clinical trials without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. CHICAGO — For patients with cancer requiring extended anticoagulant therapy ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

CHICAGO — For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban for prevention of cancer-associated ...

This means apixaban cut the clot risk by nearly half. It also improved the chances of keeping the vascular access working without further issues (32% failure rate versus 50% in the control group).